Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020:1257:181-192.
doi: 10.1007/978-3-030-43032-0_15.

Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention

Anchit Bhagat  1 , Eugenie S Kleinerman  2
Affiliations
Review

Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention

Anchit Bhagat et al. Adv Exp Med Biol. 2020.

Abstract

Doxorubicin is an anthracycline and one of the more effective chemotherapy agents used in the treatment of children, adolescents, and adults with osteosarcoma. Despite its effectiveness, cardiotoxicity is a major late effect that compromises the survival and quality of life of survivors of this and other cancers. Cardiotoxicity is the inability of the heart to pump blood through the body effectively. Doxorubicin-induced cardiotoxicity is dose dependent. Additionally, the age of the patients plays a role in susceptibility with younger patients having a greater risk for cardiotoxicity and heart failure years after treatment is complete. The exact mechanism(s) responsible for doxorubicin-induced cardiotoxicity is poorly understood, and further research needs to be done to elucidate the mechanisms. This chapter summarizes the identified mechanisms that may play a role in anthracycline-induced cardiotoxicity. We will also summarize the types of cardiomyopathies that have been described in survivors treated with doxorubicin and the current recommendations for monitoring survivor for the development of cardiomyopathies. Included will be the important search for defining early biomarkers to identify patients and survivors at risk. Finally, we will summarize some of the interventions proposed for decreasing anthracycline-induced cardiotoxicity.

Keywords: Anthracycline; Cardiotoxicity; Cardiovascular disease; Chemotherapy; Dexrazoxane; Doxorubicin; Heart failure; Osteosarcoma; Pediatric cancer.

PubMed Disclaimer

References

    1. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB (2011) Anthracycline cardiotoxicity: from bench to bedside. NIH Public Access 26(22):3777–3784. https://doi.org/10.1200/JCO.2007.14.9401.Anthracycline - DOI
    1. McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM (2017) Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther 31(1):63–75. https://doi.org/10.1007/s10557-016-6711-0 - DOI - PubMed - PMC
    1. Yang F, Teves SS, Kemp CJ, Henikoff S (2014) Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys Acta 1845(1):84–89 - PubMed
    1. Chen SH, Chan N-L, Hsieh T (2013) New mechanistic and functional insights into DNA topoisomerases. Annu Rev Biochem 82(1):139–170. https://doi.org/10.1146/annurev-biochem-061809-100002 - DOI - PubMed
    1. Champoux JJ (2001) DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70(1):369–413 - DOI

MeSH terms

LinkOut - more resources